Nyxoah's Sleep Apnea Device Receives FDA Breakthrough Tag

by Vandana Singh, Benzinga Editor

September 14, 2021 8:21 AM | 29 seconds read |

The FDA has granted Breakthrough Device Designation to Nyxoah SA NYXH Genio bilateral hypoglossal nerve stimulation system.
The system treats adult patients with moderate to severe Obstructive Sleep Apnea (OSA) and Complete Concentric Collapse (CCC) of the soft palate.
Genio system, Nyxoah's lead solution, is patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy.
Related content: Benzinga's Full FDA Calendar.
Price Action: NYXH stock is up 4.30% at $30.22 during the premarket session on the last check Tuesday.

Posted In: News Health Care Small Cap FDA Movers Trading Ideas General Briefs sleep apnea devices

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.